SBIR/STTR Research Award
IGF OT IGF DEVELOPMENT OF NOCICEPTIN RECEPTOR AGONISTS FOR ALCOHOL USE DISORDERS PERIOD OF PERFORMANCE CPFF
Award amount
$999,993Program and phase
SBIR · Phase IIAward year
2015Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ASTRAEA THERAPEUTICS, LLC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- ZNNQAFC5FXH3
- Solicitation number
- Not reported
- Topic code
- NICHD
Research abstract
Not Available
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A NOVEL APPROACH FOR PAIN TREATMENT WITHOUT OPIOID LIABILITIES
- PRECLINICAL DEVELOPMENT OF NOVEL SMOKING CESSATION PHARMACOTHERAPIES
- Nociceptin Receptor Agonists for Alcohol Use Disorders
- Development of Novel Drugs for Smoking Cessation Pharmacotherapy
- Analgesic Potential of NOP Agonists to Treat Pain in Sickle Cell Disease
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Developing RNA therapeutics for rare neurodevelopmental disorders
- SPIRIT Club CBI Pathway: A novel streaming platform for physical activity and wellness promotion for chronic brain injury survivors
- Zip-stitch for Laparoscopic Hysterectomy - Clinical Validation
- Point-of-care Testing (POCT) Tool Development for Critical Oxytocin Measurement
- Novel, Non-hormonal Therapeutic for Endometriosis
Research funding history
7 SBIR/STTR records share this UEI (2010–2016). Reported award amounts total $5,089,854. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services